Pfizer Stock Rises as 2025 Outlook in Line With Expectations

Pfizer (PFE) shares rose Tuesday morning after the pharmaceutical firm affirmed its full-year 2024 projections and issued 2025 income and adjusted revenue steering consistent with analysts’ estimates.

Pfizer stated it expects 2024 income to vary from $61 billion to $64 billion, with adjusted earnings per share (EPS) projected between $2.75 to $2.95. According to estimates compiled by Visible Alpha, analysts mission $63.01 billion in income and adjusted earnings of $2.93 per share.

For 2025, Pfizer tasks the identical income vary, whereas analysts see a slight bump to $63.24 billion. Pfizer expects its adjusted EPS will rise barely to $2.80 to $3.00, whereas analysts mission $2.89.

Pfizer Met 2024 Cost-Cutting Goals

Pfizer was profitable in its targets to chop $4 billion in prices by the top of 2024, the corporate stated Tuesday, with a further $500 million in financial savings anticipated to be realized over the subsequent 12 months. The drugmaker has returned to income progress in its two most up-to-date quarters for the primary time since gross sales of its COVID vaccine peaked.

“We additionally count on to proceed enhancing our working margins with centered monetary self-discipline,” Chief Executive Officer (CEO) Dr. Albert Bourla stated.

Pfizer shares just lately traded up 4.5% however are nonetheless down about 8% this 12 months.